AzTrials
AzTrials

HyperoxiaPhase 4NCT04133740

Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study

A Phase 4 study testing Oxygen in people with Hyperoxia and Cardiac Surgery, run by Aalborg University Hospital at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

During surgery high concentrations of supplementary oxygen are routinely administrated. However, there is increasing evidence of potential harm with liberal oxygen therapy. The hypothesis of the present study is that oxygen therapy adjusted to a normal arterial oxygen target is feasible and will attenuate the side… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hyperoxia, Cardiac Surgery, Cardiopulmonary Bypass
What is being tested?
Oxygen
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteDenmark
Study dates
1 Oct 2018to 31 Jul 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Scheduled for elective cardiac surgery either coronary artery bypass grafting and/or valve replacement performed with use of cardiopulmonary bypass

Who cannot join

  • Left ventricular ejection fraction below 30 percent

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Dept. of Intensive Care, Aalborg University Hospital

    Aalborg, 9000

Other trials in Denmark

About this study

During surgery high concentrations of supplementary oxygen are routinely administrated. However, there is increasing evidence of potential harm with liberal oxygen therapy. The hypothesis of the present study is that oxygen therapy adjusted to a normal arterial oxygen target is feasible and will attenuate the side effects of supplementary oxygen therapy. The study design is a before-and-after study in which 25 patients will follow the standard regime with high concentrations of oxygen therapy and 25 patients will be treated with oxygen to achieve a normal value of arterial oxygenation.

Read the detailed description

Background Oxygen is essential to life and supplementary oxygen therapy is routinely administrated during surgery to avoid life-threatening hypoxemia. Supplementary oxygen therapy is often given as a high and fixed fraction of inspired oxygen (FiO2) ranging from 0.60 to 1.00. As a consequence, the partial pressure of arterial oxygen (PaO2) often exceeds normal levels. There is increasing evidence of potential harm with liberal administrated oxygen therapy. Therefore, the standard regimes for oxygen therapy during surgery have to be further investigated.

The purpose of the study is to evaluate whether a regime for oxygen therapy targeting normal levels of PaO2 during elective cardiac surgery with use of cardiopulmonary bypass (CPB) and in the first postoperative day in the intensive care unit (ICU) is feasible. Additionally, metabolic changes in exhaled breath condensate and in arterial blood collected prior to surgery, before and after CPB, the first postoperative day in the ICU and the third postoperative day at the surgical ward will be evaluated.

Study Design The study design is a before-and-after study in patients scheduled for elective cardiac surgery being coronary artery bypass grafting or valve replacement or a combination of both. The first 25 patients will follow our institutional the standard regime for supplementary oxygen therapy; i.e. a minimum FiO2 of 0.60 during mechanical ventilation and at least 3 liters oxygen per minute after weaning from the ventilator in the ICU. Thereafter, another 25 patients will receive supplementary oxygen therapy to achieve a normal PaO2 defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.

Exhaled breath condensates will be collected via a mouthpiece during spontaneous breathing prior to surgery, first and third postoperative day while the condensates will be collected via the tracheal tube during mechanical ventilation. Arterial blood samples will be collected simultaneously. Exhaled breath condensates and serum samples will be divided into aliquots and stored in a -80 degree Celsius freezer until final analyses after all patients have been included.

Metabolic changes in exhaled breath condensates and in serum samples will be analyzed using nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). The spectra's will give a snapshot of all metabolites in a given sample and elucidate changes in the metabolic profiles in response to oxygen exposures.

Hypothesis The hypothesis is that oxygenation targeting is feasible and that changing the supplementary oxygen therapy to a oxygenation targeting within the normal range will reduce the FiO2 and thus the PaO2/FiO2 ratio.

Outcomes Primary outcome is the PaO2/FiO2 ratio on the third postoperative day. Secondary outcomes will be changes in metabolic profiles in exhaled breath condensates and serum samples, changes in oxygenation parameters, PaO2 and oxygen saturation, changes in time to weaning from the ventilator in the ICU, changes in FiO2 and in supplementary oxygen therapy after weaning from the ventilator, and changes in postoperative complications defined as pneumonia, arrhythmias, re-operation, and re-admission to the ICU.

Statistical analyses This is a pilot study being a feasibility before-and-after study. Based on institutional data a power calculation is performed estimating an increase in the PaO2/FiO2 ratio from 30 ± 7 kPa with the standard regime for oxygen therapy to 36 ± 7 kPa with a oxygenation targeting approach and with an alpha of 0,05 and a power of 80% (1-beta), 23 patients are needed in each group. To cover to dropouts at total of 50 patients, 25 patients in each group, will be recruited.

Data will be assessed for normality. Continuous normally distributed variables will be compared using Student t tests and reported as mean and standard deviation, while non-normally distributed data will be compared using Wilcoxon rank-sum tests and reported as median and interquartile range. All analyses will be performed by using Stata (Metrika Consulting AB, Stockholm, Sweden), Matlab.

The composition of metabolomics will be compared by multivariable analysis. For multivariate analysis, various unsupervised and supervised analyses will be carried out in Matlab (The MathWorks Inc., Natick, United States) and Python (Python Software Foundation, Delaware, United States) software with in-house scripts. Principal component analysis will be used to obtain a preliminary outlook of the data, to screen for outliers and detect clusters. Eventually, partial least squares discriminant (PLS-DA) analyses coupled to different vv rs selections algorithms will be employed to perform data reduction and classification of treatments. For validation purposes, the Venetian-Blinds cross-validation approach will be applied.

Ethics Patients will be included after an informed signed content is obtained. FiO2 of 0.60 is given routinely to patients undergoing cardiac surgery with CPB at Aalborg University Hospital. Targeting a physiological PaO2 level between 10 and 12 kPa is considered to be safe. Patients undergoing cardiac surgery is routinely maximal monitored during surgery and in the ICU. The cardiac anaesthetist in charge can charge the PaO2 target at any time.

The collection of exhaled breath condensate is painless and without any discomfort for the patient. The arterial blood sample on the third postoperative day will be performed by a cardiac anaesthetist experienced in this procedure, who will apply a subcutaneous analgesia with Lidocain 1% prior to the puncture and thus avoiding pain during the procedure. Thereafter, a manual compression will be performed for 2 minutes to minimise the risk of a haematoma. In total, four extra blood samples are collected for the metabonomics and one extra blood gas analyses. The total amount of blood extracted in the study is 12.5 mL.

All other procedures and treatments follow the standard regimes.

Being tested
Oxygen
Keywords
A before-and-after study, Oxygenation targeting
Medical subject headings
Hyperoxia, Acute Lung Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OxygenDrug

    Also called Oxygen therapy

    Liberal versus conservative oxygen therapy.

Study groups in NCT04133740
Study groupRoleWhat they receive
Standard regimeActive comparatorSupplementary oxygen is given according to the standard regime with a fraction of inspired oxygen (FiO2) of at least 0.60 during mechanical ventilation and 3 liter/minute or more after weaning from the ventilator in the intensive care unit (ICU).
Receives: Drug: Oxygen
Oxygenation targetingActive comparatorSupplementary oxygen is given to achieve a partial pressure of arterial oxygen (PaO2) within the normal range defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.
Receives: Drug: Oxygen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. P/F ratio

    Ratio of fraction of inspired oxygen (FiO2) and partial pressure of arterial oxygen (PaO2)

    Measured: Third postoperative day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Oct 2019
  2. Study start1 Oct 2018
  3. Primary completion15 Jul 2019
  4. Study completion31 Jul 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Model description
A before-and-after study in which the first half to the planned patients are following the standard regime for oxygen therapy with a fixed amount and the other half of the patients receive oxygen therapy to achieve normal levels of partial pressure of arterial oxygen.
Masking
None (open label)
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04133740
Sponsor's protocol ID
AAUH-ANAESTH-01
Status last verified
Oct 2019
First submitted
18 Oct 2019
Last updated
28 Oct 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Oxygen in people with Hyperoxia and Cardiac Surgery, run by Aalborg University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

P/F ratio (time frame: Third postoperative day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in